In Q2 2025, Tyra Biosciences posted a net loss of $18.1 million with no revenue, reflecting ongoing investment in its clinical-stage precision oncology programs. R&D expenses totaled $14.4 million, and the company maintained a strong cash position of $275.1 million.

Tyra Biosciences, Inc. reported a net loss of $28.1 million for the three months ended March 31, 2025, compared to a net loss of $18.2 million for the same period in 2024. This increased loss was primarily due to a significant rise in total operating expenses, which reached $31.85 million, up from $22.32 million in the prior year. The company's cash, cash equivalents, and marketable securities stood at $318.9 million as of March 31, 2025, which is expected to fund operations through at least 2027.

Tyra Biosciences reported a net loss of $25.571 million for Q4 2024, with total assets of $363.558 million and cash and cash equivalents of $91.966 million. The company advanced TYRA-300 into three Phase 2 studies and cleared INDs for SURF302 and BEACH301, demonstrating significant clinical progress.

Tyra Biosciences reported its Q3 2024 financial results, featuring positive interim data for TYRA-300 in mUC, progress in expanding TYRA-300 development into NMIBC, clearance for a Phase 2 achondroplasia study, and the appointment of Doug Warner as CMO. The company's cash reserves are expected to last through at least 2026.

Tyra Biosciences reported a net loss of $18.7 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities were $373.8 million as of June 30, 2024.

Tyra Biosciences reported a net loss of $18.2 million for the first quarter of 2024. The company's research and development expenses were $17.2 million, and general and administrative expenses were $5.1 million. As of March 31, 2024, Tyra had cash, cash equivalents, and marketable securities of $382.5 million.

Tyra Biosciences reported a net loss of $22.8 million for the fourth quarter of 2023, compared to a net loss of $12.9 million for the same period in 2022. Research and development expenses were $20.7 million, and general and administrative expenses were $5.0 million for the quarter. The company's cash, cash equivalents, and marketable securities totaled $203.5 million as of December 31, 2023, which is expected to support operations through at least 2026, especially after the $200 million PIPE in Q1 2024.

Tyra Biosciences reported a net loss of $21.2 million for the third quarter of 2023 and highlighted the advancement of TYRA-300 in the SURF301 oncology study, positive preclinical data for achondroplasia, and the expected initiation of the TYRA-200 Phase 1 study by the end of 2023. The company's cash and cash equivalents totaled $215.7 million as of September 30, 2023.

Tyra Biosciences reported a net loss of $13.3 million for the second quarter of 2023 and had cash and cash equivalents of $232.4 million as of June 30, 2023. The company is advancing its pipeline, including TYRA-300 and TYRA-200, and received Orphan Drug Designation for TYRA-300 in achondroplasia.

Tyra Biosciences reported a net loss of $11.9 million for the first quarter of 2023, with a strong cash position of $241.7 million as of March 31, 2023. The company continued to advance its SURF301 Phase 1/2 clinical study for oncology and expanded the development of TYRA-300 into achondroplasia. The IND for TYRA-200 was cleared, with a Phase 1 study on track for the second half of 2023.

Tyra Biosciences reported a net loss of $12.9 million for the fourth quarter of 2022. The company's cash and cash equivalents stood at $251.2 million as of year-end 2022.

Tyra Biosciences reported a net loss of $12.5 million for Q3 2022, with cash and cash equivalents totaling $263.2 million as of September 30, 2022. The company's pipeline development remains on track, including the planned initiation of the SURF301 study and the IND filing for TYRA-200 by the end of 2022.

Tyra Biosciences reported a net loss of $15.1 million for the second quarter of 2022. The FDA cleared the company to proceed with its SURF301 study of TYRA-300, and the IND for TYRA-200 is on track to be filed in the second half of 2022. The company had cash and cash equivalents of $275.1 million as of Q2 2022.

Tyra Biosciences reported a net loss of $14.8 million for the first quarter of 2022, with cash and cash equivalents totaling $292.5 million as of March 31, 2022. The company is on track to file INDs for TYRA-300 and TYRA-200 in 2022 and is progressing its pipeline.

Tyra Biosciences reported a net loss of $9.9 million for the fourth quarter of 2021, compared to a net loss of $3.7 million for 2020. The company's research and development expenses were $7.2 million for the quarter, and they ended the year with $302.2 million in cash and cash equivalents.